For example, the inflammation and metabolic disorders caused by blocking calcium mobilization-mediated NLRP3 inflammasome activation via G protein-coupled receptor 35 (GPR35) are ameliorated by kynurenic acid, which is produced by a PLP enzyme, kynurenine aminotransferase, from kynurenine [76]. Here, GPR35 is linked to metabolic disease.